Company Overview
Propanc Biopharma, Inc. operates as a development-stage biopharmaceutical healthcare company focused on the creation of novel cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancers in Australia. The company's lead product candidate is PRP, an intravenous injection proenzyme treatment designed to address these specific malignancies, positioning the firm within the specialized field of oncology drug development. This entity functions within the broader healthcare sector and the biotechnology industry, sectors characterized by high research and development expenditures and long timelines to market approval. As of the latest data, the company maintains a market capitalization of $1.64M and employs a workforce consisting of 1 individual, while annual revenue is listed as unavailable in the current reporting period. The combination of a market cap under $2 million and the absence of reported revenue indicates that Propanc Biopharma, Inc. is a micro-cap entity in the early stages of its commercialization or clinical development lifecycle. This scale suggests the company is currently prioritizing asset development and regulatory pathways over generating immediate cash flow or achieving profitability, which is typical for development-stage biotechnology firms.
Financial Health
The company reports a net income of $-67,000,184 and an EBITDA of $-65,101,756 over the trailing twelve months, while revenue is not available for calculation. The substantial gap between the negligible revenue and the significant net loss reveals a cost structure dominated by high burn rates associated with drug discovery, clinical trials, and regulatory filing expenses rather than cost of goods sold. Despite the negative net income, the company reports free cash flow of $14.25M, a metric that suggests a potential discrepancy in how cash is being classified or indicates specific one-time cash inflows relative to the operating burn, though typically free cash flow aligns closely with net income for biotech firms at this stage. All three reported margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company is not yet generating profitable operations from its sales or cost structure. The balance sheet shows cash holdings of $561,237 against total debt of $649,216, resulting in a debt-to-equity ratio of 5.67, which classifies the financial position as highly leveraged relative to its equity base. However, the current ratio stands at 2.13, which indicates that the company possesses sufficient current assets to cover its short-term liabilities more than twice over, providing a layer of liquidity protection despite the debt load. Return on Equity is listed at -1811.7% and Return on Assets is -535.7%, figures that reveal that management has not yet achieved positive returns on the capital deployed, reflecting the inherent risk and high capital requirements of the biotechnology industry.
Valuation Assessment
The trailing P/E ratio is 0.00 and the forward P/E is unavailable, a disparity that implies the company has no earnings to value and that future earnings expectations are either too speculative or non-existent for traditional valuation models to apply. The price-to-book ratio is 0.13, indicating that the market values the company's equity at significantly less than its book value, which often occurs when assets are recorded at historical costs rather than their potential replacement or development value. Alternative valuation metrics such as price-to-sales and EV/EBITDA are unavailable or negative at -0.04, suggesting that standard multiple-based valuation comparisons with profitable peers are not currently applicable to this asset. The stock has experienced extreme volatility within the past year, trading between a 52-week high of $11.00 and a 52-week low of $0.10. Given the wide range between these extremes, the current price sits in a highly compressed position relative to the historical trading band, reflecting the speculative nature of the investment. The beta value is 3.48, which signifies that the stock price is approximately 3.48 times more volatile than the broader market, exposing investors to substantial price swings driven by small changes in the underlying biotechnology sector sentiment.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both unavailable, preventing a direct comparison of whether earnings are growing faster or slower than revenue in the current fiscal context. Because the company does not pay a dividend, the dividend yield and payout ratio are both N/A, meaning the company reinvests all available capital and any generated cash flow back into research and development activities rather than distributing income to shareholders. This reinvestment strategy is characteristic of development-stage firms that must fund ongoing clinical trials and regulatory processes to advance their product pipeline toward market approval. The overall growth and income profile is defined by a complete lack of historical earnings data and dividend distributions, relying entirely on the successful execution of future product candidates to generate returns for shareholders.